Precision NanoSystems Announces New Vice President of Business Development

Press Release

February 23, 2018

Precision NanoSystems (PNI) announced today the appointment of Padma Kodukula as Vice President for Business Development, further strengthening its executive team as the company continues reinforcing the foundation for long-term growth.

“Padma has worked in the diagnostic, pharmaceutical and research industries with success in closing strategic partnerships, leading the development and launch of multiple technology platforms and therapeutics,” said Euan Ramsay, COO and Co-founder of PNI. “The proven critical thinking she brings to PNI coupled with her comprehensive understanding of the markets we address will position PNI to bring high-value solutions to new clients and in new customer channels.”

Padma will be responsible for global business development activities, including strategic commercial deals and alliance management. Prior to joining PNI Padma worked in the business development team at Human Longevity Inc. where she fostered collaborative partnerships with pharma, academia and health systems to deliver on the promise of genomics and data analytics to revolutionize healthcare. Before that, Padma spent 15 years in business development and program management roles at Life Technologies, where she managed the qPCR and capillary electrophoresis platforms and enabled collaborative partnerships with molecular diagnostics and pharmaceutical companies, and in various program management and alliance management roles at Prometheus Laboratories, Biosite, Pfizer and BD Biosciences.

She received her PhD in viral immunology from University of Illinois at Chicago and MBA from San Diego State University.

About Precision NanoSystems, Inc.

Precision NanoSystems Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI’s proprietary NanoAssemblr Platform enables the rapid, reproducible and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.

Contact for further information or follow-up:
Jane Alleva
Global Marketing Manager
Precision NanoSystems
Phone: 1 888 618 0031, ext 140
Mobile: 1 778 877 5473
www.precisionnanosystems.com


IN THE NEWS

Press Release

The NanoAssemblr Blaze moves nanomedicine development from the preliminary stages of formulation screening and iteration onto large batch manufacturing of nanoparticles suitable for toxicology screening and analysis. Based on the proven N...

Read More


Press Release

SAN DIEGO, Calif., and Vancouver, British Columbia/PR Newswire/July 26, 2022 --In a move that signifies the heightened focus on mRNA as a key tool in human health, Precision NanoSystems (PNI) and Replicate Bioscience will enter a licensing agreement to accelerate the creation, sc...
Read More